Cardiovascular Drugs and Therapy : Impact Factor & More
eISSN: 1573-7241pISSN: 0920-3206
Share this on:
Key Metrics
CiteScore 
5.6
Eigenfactor
0.001 - 0.005
Impact Factor
< 5
SJR
Q1Pharmacology
SNIP
0.93
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Cardiovascular Drugs and Therapy
Cardiovascular Drugs and Therapy Journal Specifications
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 1987 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Cardiovascular Drugs and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Cardiovascular Drugs and Therapy
Correction to: The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary Intervention (PCI): Affectability of Rapid Genetic Testing.
- 1 Jun 2026
- Cardiovascular drugs and therapy
Refining Antithrombotic Therapy in Coronary Artery Ectasia: A Call for Phenotype-Driven Trials and Precision Dosing.
- 1 Jun 2026
- Cardiovascular drugs and therapy
Mitochondria at the Heart of Ischemia-Reperfusion (I/R) Injury: the HOXB5-Sirt5 Axis.
- 1 Jun 2026
- Cardiovascular drugs and therapy
Anticoagulant versus Antiplatelet Therapy After Acute Coronary Syndromes in Patients with Coronary Artery Ectasia: A Retrospective Cohort Study.
- 1 Jun 2026
- Cardiovascular drugs and therapy
Can It Be that Metabolic Syndrome Protect against Breast Cancer.
- 1 Jun 2026
- Cardiovascular drugs and therapy
Paeoniflorin Alleviates Coronary Artery Lesions in Kawasaki Disease by Activating NRF2 Pathway and Inhibiting CYP2E1 Expression.
- 1 Jun 2026
- Cardiovascular drugs and therapy
Correction to: The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary Intervention (PCI): Affectability of Rapid Genetic Testing.
- 1 Jun 2026
- Cardiovascular drugs and therapy
Refining Antithrombotic Therapy in Coronary Artery Ectasia: A Call for Phenotype-Driven Trials and Precision Dosing.
- 1 Jun 2026
- Cardiovascular drugs and therapy
Mitochondria at the Heart of Ischemia-Reperfusion (I/R) Injury: the HOXB5-Sirt5 Axis.
- 1 Jun 2026
- Cardiovascular drugs and therapy
Anticoagulant versus Antiplatelet Therapy After Acute Coronary Syndromes in Patients with Coronary Artery Ectasia: A Retrospective Cohort Study.
- 1 Jun 2026
- Cardiovascular drugs and therapy
Can It Be that Metabolic Syndrome Protect against Breast Cancer.
- 1 Jun 2026
- Cardiovascular drugs and therapy
Paeoniflorin Alleviates Coronary Artery Lesions in Kawasaki Disease by Activating NRF2 Pathway and Inhibiting CYP2E1 Expression.
- 1 Jun 2026
- Cardiovascular drugs and therapy
FAQs on Cardiovascular Drugs and Therapy
How long has Cardiovascular Drugs and Therapy been actively publishing? 
What is the publishing frequency of Cardiovascular Drugs and Therapy?
How many articles did Cardiovascular Drugs and Therapy publish last year?
What is the eISSN & pISSN for Cardiovascular Drugs and Therapy?
What is Citescore for Cardiovascular Drugs and Therapy?
What is SNIP score for Cardiovascular Drugs and Therapy?
What is the SJR for Cardiovascular Drugs and Therapy?
Who is the publisher of Cardiovascular Drugs and Therapy?
